Abstract

Descriptive Report of Individual State Responses to Personal Protective Equipment Shortages for Pharmacy Practice During the Covid-10 Pandemic

Author(s): Roberts Patricia A, Eberwein Samuel M, Youmans Danielle, Amerine Lindsey B

Issue: Mar/Apr 2021 - Volume 25, Number 2

Page(s): 109-113

Download in electronic PDF format for $75
  • Descriptive Report of Individual State Responses to Personal Protective Equipment Shortages for Pharmacy Practice During the Covid-10 Pandemic Page 1
  • Descriptive Report of Individual State Responses to Personal Protective Equipment Shortages for Pharmacy Practice During the Covid-10 Pandemic Page 2
  • Descriptive Report of Individual State Responses to Personal Protective Equipment Shortages for Pharmacy Practice During the Covid-10 Pandemic Page 3
  • Descriptive Report of Individual State Responses to Personal Protective Equipment Shortages for Pharmacy Practice During the Covid-10 Pandemic Page 4
  • Descriptive Report of Individual State Responses to Personal Protective Equipment Shortages for Pharmacy Practice During the Covid-10 Pandemic Page 5

Note: Electronic version includes supplemental material.

Abstract

The objective of this study was to describe the response by state boards of pharmacy pertaining to personal protective equipment shortages during the early phase of the COVID-19 pandemic. All webpages of state boards of pharmacy were independently reviewed for written guidance pertaining to personal protective equipment conservation strategies in sterile compounding and deviations from United States Pharmacopeia General Chapter <797> standards; each guidance was then reviewed for referenced sources. Of 52 state pharmacy regulatory bodies, 38 (73.08%) provided guidance to modifying personal protective equipment use during sterile compounding activities to mitigate supply shortages. The references for each guidance varied, however, most referenced CriticalPoint, LLC or the United States Pharmacopeia. A few of the guidance documents from boards also permitted other deviations from United States Pharmacopeia Chapter <797> standards. Early in the pandemic, pharmacists within sterile compounding practices had to conserve personal protective equipment while mitigating contamination risk. Pharmacists looked to state boards of pharmacy for guidance. This report shows a high level of state response to the personal protective equipment shortage induced by the pandemic.

Related Keywords

  • COVID-19 pandemic
  • coronavirus
  • personal protective equipment
  • PPE shortage
  • state boards of pharmacy
  • PPE conservation strategies
  • supply chain disruption
  • United States Pharmacopeia Chapter <797>
  • USP
  • U.S. Food and Drug Administration
  • regulation
  • sterile compounding standards
  • compounded sterile preparations
  • microbial contamination
  • beyond use date modification
  • environmental contaminant testing

Related Categories

  • ENVIRONMENTAL
  • STERILE PREPARATIONS
  • UNITED STATES PHARMACOPEIA CONVENTIONS
  • INFECTIOUS DISEASE
  • PROFESSIONAL ISSUES

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy		 Title/Author
(Click for Abstract / Details / Purchase)
Mar/Apr 2021
Pg. 109-113
Descriptive Report of Individual State Responses to Personal Protective Equipment Shortages for Pharmacy Practice During the Covid-10 Pandemic
Author(s): Roberts Patricia A, Eberwein Samuel M, Youmans Danielle, Amerine Lindsey B
Jul/Aug 2020
Pg. 287-295
Pharmacies on the Frontline: Responding to the COVID-19 Pandemic
Author(s): McElhiney Linda F
Jan/Feb 2020
Pg. 30-36
Quality Control: Personal Protective Equipment for Use When Handling Hazardous Drugs
Author(s): Dillon L R
Jan/Feb 2023
Pg. 12-21
Compounding for the Treatment of COVID-19 and Long COVID, Part 1: Terminology, Mutations, and Variants
Author(s): Riepl Mike
Jul/Aug 2023
Pg. 284-293
Compounding for the Treatment of COVID-19 and Long COVID, Part 4: The Legacy of Chronic COVID
Author(s): Riepl Mike, Kaiser Joe
Sep/Oct 2023
Pg. 368-380
Compounding for the Treatment of COVID-19 and Long COVID, Part 5: Associated Conditions, Prophylaxis, and Effective Treatment
Author(s): Riepl Mike, Kaiser Joe
Mar/Apr 2023
Pg. 98-107
Compounding for the Treatment of COVID-19 and Long COVID, Part 2: Manifestations of Infection, Nomenclature, Transmission, and Treatment
Author(s): Riepl Mike
May/Jun 2023
Pg. 192-200
Compounding for the Treatment of COVID-19 and Long COVID, Part 3: The Role of Toll-like Receptors in SARS-CoV-2 Infection and COVID Development
Author(s): Riepl Mike, Kaiser Joe
Jul/Aug 2020
Pg. 268
PreScription: COVID-19 and Compounding Pharmacists
Author(s): Allen Loyd V Jr
Sep/Oct 2020
Pg. 358-364
Cocamidopropyl Betaine Surfactant 0.075% Solution in Physiological Serum for Hygiene Process of COVID-19 Intubated Patients
Author(s): Nogales Luis Marcos, Jiménez Labaig Luis, Abarca Lachén Edgar, Gil Melcón María, López-Nieves Marisol
Sep/Oct 2020
Pg. 371-379
Safety Standards in Pharmaceutical Compounding, Part 2: A Closer Look at Agency Information, Oversight, and Assistance
Author(s): Greeson Nicole MH, Mixon William, Allan W Chris
May/Jun 2022
Pg. 182-186
Art of Pharmacy v. State
Author(s): Standridge Rob
Mar/Apr 2022
Pg. 100-109
Allowing Compounding Pharmacies to Address Drug Shortages
Author(s): Broughel James
Jan/Feb 2018
Pg. 7-16
Certification, Accreditation, and Credentialing for 503A Compounding Pharmacies
Author(s): Pritchett Jon, McCrory Gary, Kraemer Cheri, Jensen Brenda, Allen Loyd V Jr
Jul/Aug 2021
Pg. 268
PreScription: Endemics, Epidemics, and Pandemics
Author(s): Allen Loyd V Jr
May/Jun 2007
Pg. 178
PreScription: State or Federal Control of Pharmacy Practice
Author(s): Allen Loyd V Jr
Jul/Aug 2021
Pg. 296-297
A Permanent Path for Urgent-use Compounding? APC-supported Legislation Would Allow 503As to Fill Gaps in Coverage When 503Bs Cannot
Author(s): Brunner Scott
Nov/Dec 2015
Pg. 453-463
Applying Quality of Design Concepts to Pharmacy Compounding
Author(s): Timko Robert J
Jan/Feb 2017
Pg. 4
PreScription: Compounding Pharmacy Issues for 2017
Author(s): Allen Loyd V Jr
May/Jun 2008
Pg. 216-229
Microbial Air-Sampling Equipment, Part 1: Meeting United States Pharmacopeia Chapter <797> Standards
Author(s): Kastango Eric S